Raya Therapeutic Announces Addition of RT1972 (Cutamesine) to EXPERTS-ALS Platform Trial, Joining RT1999 (Smilagenin)
Second Raya CARES compound to be evaluated in the UK's NIHR-funded ALS platform trial with both compounds expected to
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
Second Raya CARES compound to be evaluated in the UK’s NIHR-funded ALS platform trial with both compounds expected to begin dosing early-mid 2027.
MONTREAL, QUEBEC, CANADA, November 16, 2026 /EINPresswire.com/ — Raya Therapeutic Inc. (“Raya”), a mission-driven company focused on the treatment of ALS and other neurodegenerative diseases, announces that RT1972 (cutamesine) will be included as a treatment arm in the EXPERTS-ALS (EXPErimental medicine Route To Success in ALS) Platform Trial, led by the University of Sheffield and the University of Oxford. This is in addition to RT1999 (smilagenin), Raya’s first compound selected for the platform, as announced in March 2026. Both treatment arms are expected to dose their first patients in early-mid 2027.
The selection of a second Raya compound marks a significant milestone for the company. It is a further independent scientific endorsement of Raya’s strategy of developing multiple clinical-stage compounds that act on distinct pathways involved in motor neuron degeneration. Moreover, the data from this clinical trial will inform future clinical development of RT1972 for the treatment of ALS, and potentially for other indications.
“ALS is a highly heterogeneous disease, and assessing therapeutics with different mechanisms of action on EXPERTS-ALS, will lead to prompt prioritization of therapeutics for continued development. After diligent review, our team is pleased to welcome RT1972 onto the platform. The use of blood neurofilament light chain as a primary endpoint will identify within months whether a drug is likely slowing the disease progression, so that the most promising candidates can move rapidly into larger trials.” said Professor Chris McDermott, Chief Investigator of EXPERTS-ALS, University of Sheffield.
“Having a second compound selected for EXPERTS-ALS is a strong validation of the science behind the Raya CaRES Pipeline,” said Anjan Aralihalli, President of Raya Therapeutic. “We are excited for the potential of EXPERTS-ALS to identify a signal of RT1972 on blood neurofilament levels in participants with ALS. We are grateful to Professors McDermott and Turner and the EXPERTS-ALS team, and look forward to our collaboration with them to bring both RT1999 and RT1972 to people living with ALS as quickly and safely as possible.”
About the EXPERTS-ALS Platform Trial
EXPERTS-ALS is led by Professor Chris McDermott at the University of Sheffield and Professor Martin Turner at the University of Oxford. It involves approximately 17 clinical centres across the UK and is sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. It is a flagship study within the broader portfolio of the UK MND Research Institute, funded by the National Institute for Health and Care Research (NIHR) through its Efficacy and Mechanism Evaluation (EME) programme and Biomedical Research Centre Capacity Building funding schemes. Patient charities MND Association, My Name‘5 Doddie Foundation, the Darby Rimmer Foundation, and medical research charity LifeArc are providing additional support.
The platform screens candidate drugs in people living with ALS to quickly identify those most likely to be of clinical benefit. Each arm is expected to enrol approximately 80 participants treated for six months. The primary measure is the blood biomarker neurofilament light chain (NfL), which is elevated in ALS and correlates with disease progression and survival. Function, quality of life and target engagement are also assessed, and multiple interim analyses support rapid decision-making. Drugs showing an early signal of disease modification can then be prioritised for larger, placebo-controlled trials.
About RT1972 (Cutamesine): Mechanism of Action
RT1972 (cutamesine) is an investigational, orally administered, small-molecule sigma-1 receptor agonist that crosses the blood–brain barrier. The sigma-1 receptor is a chaperone protein at multiple locations in the cell, including between the endoplasmic reticulum and mitochondria. There it contributes to many processes, among others calcium signalling, cellular stress responses, and mitochondrial functioning. RT1972 is neuroprotective across a host of neurodegenerative disease models.
Preclinical Evidence in ALS Models
In the SOD1-G93A mouse model of ALS, treatment with RT1972 significantly extended survival. In cellular models, treatment with RT1972 protected neuronal survival in a concentration-dependent manner and activated pro-survival Akt and ERK signalling. Additionally, treatment with RT1972 increased axonal outgrowth and protected against TDP-43 mislocalization.
Clinical Experience
RT1972 has been evaluated in Phase 1 and Phase 2 clinical studies in healthy volunteers and in various CNS indications. Across these studies, RT1972 was generally well-tolerated.
About RT1999 (Smilagenin)
RT1999 (smilagenin) is an investigational, orally administered small molecule that crosses the blood–brain barrier and acts as a neurotrophic factor modulator. See March 9, 2026 Press Release for more information.
Members of the Raya team will be at Jefferies Healthcare/London Life Sciences Week November 16-19, 2026 and welcome the opportunity to discuss Raya’s broader pipeline with interested parties.
About Raya Therapeutic
Raya is a mission-driven company focused on the treatment of ALS, PD and other neurodegenerative diseases, leveraging the latest techniques for the selection and development of disease-modifying therapies. The company has a robust pipeline of five distinct clinical-stage compounds (Raya CARES Pipeline) that each target different pathways involved in motor neuron degeneration in ALS. The compounds were in-licensed following a rigorous selection process based on biological plausibility, clinical target engagement and functional clinical effects reflective of efficacy. This diversified approach enables the development of combination therapies, which may have a significant impact on disease progression. For more information, visit www.rayatherapeutic.com
About NIHR
The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:
• Funding high quality, timely research that benefits the NHS, public health and social care;
• Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
• Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
• Attracting, training and supporting the best researchers to tackle complex health and social care challenges;
• Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
• Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries.
NIHR is funded by the Department of Health and Social Care. Its work in low- and middle-income countries is principally funded through UK international development funding from the UK government.
Anjan Aralihalli
Raya Therapeutic, Inc.
admin@rayatherapeutic.com
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![]()
Media gallery



